Authors,AuthorsWithAffiliationNameFull,AuthorsWithAffiliationNameInitial,AuthorsWithAffiliationAffiliation,AllAffiliations,Abstract,date_year,date_monthY,date_mdY,PMID,PMCID,DOI,JournalTitle,ArticleTitle,PageStart,PageEnd,Volume,Issue,MeSH_Terms,MeSH_Major,MeSH_with_Qualifiers,Keywords,DocumentType
"Bress AP, Anderson TS, Flack JM, Ghazi L, Hall ME, Laffer CL, Still CH, Taler SJ, Zachrison KS, Chang TI, American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology",,,,[''],"Over the past 3 decades, a substantial body of high-quality evidence has guided the diagnosis and management of elevated blood pressure (BP) in the outpatient setting. In contrast, there is a lack of comparable evidence for guiding the management of elevated BP in the acute care setting, resulting in significant practice variation. Throughout this scientific statement, we use the terms acute care and inpatient to refer to care received in the emergency department and after admission to the hospital. Elevated inpatient BP is common and can manifest either as asymptomatic or with signs of new or worsening target-organ damage, a condition referred to as hypertensive emergency. Hypertensive emergency involves acute target-organ damage and should be treated swiftly, usually with intravenous antihypertensive medications, in a closely monitored setting. However, the risk-benefit ratio of initiating or intensifying antihypertensive medications for asymptomatic elevated inpatient BP is less clear. Despite this ambiguity, clinicians prescribe oral or intravenous antihypertensive medications in approximately one-third of cases of asymptomatic elevated inpatient BP. Recent observational studies have suggested potential harms associated with treating asymptomatic elevated inpatient BP, which brings current practice into question. Despite the ubiquity of elevated inpatient BPs, few position papers, guidelines, or consensus statements have focused on improving BP management in the acute care setting. Therefore, this scientific statement aims to synthesize the available evidence, provide suggestions for best practice based on the available evidence, identify evidence-based gaps in managing elevated inpatient BP (asymptomatic and hypertensive emergency), and highlight areas requiring further research.",2024,Aug 2024,,38804130,,10.1161/HYP.0000000000000238,"Hypertension (Dallas, Tex. : 1979)",The Management of Elevated Blood Pressure in the Acute Care Setting: A Scientific Statement From the American Heart Association.,e94,e106,81,8,Humans; Hypertension; Antihypertensive Agents; American Heart Association; United States; Blood Pressure; Practice Guidelines as Topic; Blood Pressure Determination,Hypertension; Antihypertensive Agents; American Heart Association,"Humans; Hypertension/diagnosis, drug therapy, physiopathology, therapy; Antihypertensive Agents/therapeutic use; American Heart Association; United States; Blood Pressure/physiology, drug effects; Practice Guidelines as Topic; Blood Pressure Determination/methods, standards",AHA Scientific Statements; antihypertensive agents; blood pressure; hospitalization; hypertension; inpatients,"Journal Article, Review"
"Armoundas AA, Ahmad FS, Bennett DA, Chung MK, Davis LL, Dunn J, Narayan SM, Slotwiner DJ, Wiley KK, Khera R, American Heart Association Data Science and Precision Medicine Committee of the Council on Genomic and Precision Medicine and Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council",,,,[''],"Wearable devices are increasingly used by a growing portion of the population to track health and illnesses. The data emerging from these devices can potentially transform health care. This requires an interoperability framework that enables the deployment of platforms, sensors, devices, and software applications within diverse health systems, aiming to facilitate innovation in preventing and treating cardiovascular disease. However, the current data ecosystem includes several noninteroperable systems that inhibit such objectives. The design of clinically meaningful systems for accessing and incorporating these data into clinical workflows requires strategies to ensure the quality of data and clinical content and patient and caregiver accessibility. This scientific statement aims to address the best practices, gaps, and challenges pertaining to data interoperability in this area, with considerations for (1) data integration and the scope of measures, (2) application of these data into clinical approaches/strategies, and (3) regulatory/ethical/legal issues.",2024,Jun 2024,,38779844,PMC11703599,10.1161/HCG.0000000000000095,Circulation. Genomic and precision medicine,Data Interoperability for Ambulatory Monitoring of Cardiovascular Disease: A Scientific Statement From the American Heart Association.,e000095,e000095,17,3,"Humans; American Heart Association; Cardiovascular Diseases; Health Information Interoperability; Monitoring, Ambulatory; United States; Wearable Electronic Devices","American Heart Association; Cardiovascular Diseases; Monitoring, Ambulatory","Humans; American Heart Association; Cardiovascular Diseases/therapy, diagnosis; Health Information Interoperability; Monitoring, Ambulatory/methods, standards; United States; Wearable Electronic Devices",AHA Scientific Statements; International Classification of Diseases; ambulatory care; cardiovascular diseases; electronic health records; wearable electronic devices,Journal Article
"Chopra HK, Wander GS, Ponde CK, Nanda NC, Khullar D, Venugopal K, Ray S, Nair T, Rana DS, Kher V, Sawhney J, Kasliwal RR, Abdullakutty J, Chakraborty R, Chandra P, Bansal S, Kumar V, Pancholia AK, Kapoor A, Prakash S, Saxena A, Rastogi V, Sharma V, Arora YK, Dasbiswas A, Bhargava M, Jaswal A, Bhargava K, Bhatia M, Omar AK, Khanna NN, Passey R, Bhalla D, Vijayalakshmi IB, Bhalla AK, Moorthy A, Isser HS, Mishra SS, Routray S, Tandon V, Sinha A, Bansal M, Jain P, Hotchandani R, Jain D, Katyal VK, Gulati S, Tandon R, Jaggi S, Sehgal B, Gupta V, Mehrotra R, Krishnamani NC, Pathak SN, Yadav MS, Chawla R, Shastry NR, Chatterjee N, Samajdar SS, Pal J, Tiwaskar M",,,,"['cardiologist, department of cardiac sciences, fortis healthcare, delhi, india.', 'head, department of cardiology, prs hospital, trivandrum, kerala, india.', 'chairman, department of nephrology and kidney transplant, epitome kidney urology institute & lions hospital, delhi, india.', 'professor emeritus, former hod, department of pediatric cardiology, shri jayadeva institute of cardiovascular sciences and research, bengaluru, karnataka, india.', 'senior consultant cardiologist, department of cardiology, jay prabha medanta super speciality hospital, patna, bihar, india.', 'professor of medicine and cardiovascular disease, department of medicine, uab heersink school of medicine, university of alabama at birmingham (uab), birmingham, alabama, united states of america.', 'ex-director, department of icvs (cardioogy), institute of post graduate medical education & research (ipgmer); chief cardiologist, department of cardiology, dasbiswas clinic, kolkata, west bengal, india.', 'hod, department of medicine, positron multi-speciality hospital; formerly senior professor and hod, department of medicine, pt bd sharma postgraduate medical institute of medical science, rohtak, haryana, india.', 'senior vice chairman and head of cardiology, department of cardiology, medica super specialty hospitals, kolkata, west bengal, india.', 'director and head, department of nephrology and transplant service, blk-max super speciality hospital, delhi; max hospital, gurugram, haryana, india.', 'principal director and head, department of imaging, fortis escorts heart institute; delhi, india.', 'principal director, department of nephrology and kidney transplant, fortis healthcare, delhi, india.', 'senior consultant physician, department of cardiology, hero dmc heart institute, ludhiana, punjab, india.', 'professor, department of internal medicine, institute of post graduate medical education & research (ipgmer), kolkata, west bengal, india.', 'hod, department of medicine and preventive cardiology, arihant hospital, indore, madhya pradesh, india.', 'senior consultant, department of interventional cardiology, max super speciality hospital, delhi, india.', 'executive director, department of cardiac pacing and electrophysiology, national heart institute of all india heart foundation, delhi, india.', 'professor and head of cardiology, department of cardiology, hero dmc heart institute, dayanand medical college & hospital, ludhiana, punjab, india.', 'department of cardiology, vardhman mahavir medical college & safdarjung hospital, delhi, india.', 'consultant, department of noninvasive cardiology, medanta moolchand heart centre, delhi, india.', 'emeritus professor, department of cardiology, pushpagiri institute of medical sciences, thiruvalla, kerala, india.', 'vice ceo and head, department of cardiology services, national heart institute of all india heart foundation, delhi, india.', 'cardiologist, department of cardiology, med n heart clinic, cuttack, odisha, india.', 'senior consultant, department of interventional cardiology, indraprastha apollo hospital, delhi, india.', 'cardiologist, department of cardiology, national heart institute, delhi, india.', 'advisor, apollo group of hospitals; senior consultant and coordinator, department of cardiology and vascular services, indraprastha apollo hospital; delhi, india.', 'clinical pharmacologist and consultant physician, department of pharmacology, diabetes and allergy-asthma therapeutics specialty clinic; independent clinical pharmacologist, kolkata, west bengal, india, corresponding author.', 'consultant cardiologist, department of cardiology, sir ganga ram hospital; delhi, india.', 'professor, department of cardiology, institute of medical sciences, banaras hindu university, varanasi, uttar pradesh, india.', 'senior consultant diabetologist, director, north delhi diabetes centre, delhi, india.', 'senior consultant cardiologist, department of cardiology, medanta-moolchand heart centre; chairman cme, moolchand medcity, delhi, india; country head, american heart association; chairman, world wellness foundation and world heart academy, ludhiana, punjab, india.', 'consultant and head, department of nephrology and transplant, moolchand hospital, delhi, india.', 'senior consultant cardiologist, department of cardiology, lisie hospital, kochi, kerala, india.', 'senior director, department of clinical and preventive cardiology, medanta-the medicity, gurugram, haryana, india.', 'honorary teaching faculty, all india institute of medical sciences; consultant physician, kishori ram hospital, bathinda, punjab, india.', 'emeritus consultant nephrologist, department of nephrology, sir ganga ram hospital, delhi, india.', 'principal director and chief of cath lab, department of cardiac sciences, max super speciality hospital, delhi, india.', 'chairman, department of interventional cardiology, medanta heart institute, medanta - the medicity, delhi, india.', 'chairman, department of nephrology, sir ganga ram hospital, delhi, india.', 'professor, department of cardiology, srirama chandra bhanj medical college & hospital (scb medical college), cuttack, odisha, india.', 'professor, department of medicine, r g kar medical college & hospital, sdmc; dean, indian college of physicians, kolkata, west bengal, india.', 'director and head, department of noninvasive cardiology, max super speciality hospital, delhi, india.', 'professor and hod, department of cardiology, safdarjung hospital, delhi, india.', 'director, department of invasive cardiology, amri hospitals, kolkata, west bengal, india.', 'senior consultant cardiologist, department of cardiology, shrikrishna institute of management and science, chennai, tamil nadu, india.', 'associate director, in-charge, department of cardiology, noninvasive cardiac laboratory, max smart super speciality hospital, delhi, india.', 'consultant physician and diabetologist, shilpa medical research centre, mumbai, maharashtra; editor-in-chief, journal of the association of physicians of india.', 'consultant nephrologist, department of nephrology, sri balaji action medical institute, delhi, india.', 'director, department of interventional cardiology, max super speciality hospital, delhi, india.', 'executive director and chief cardiologist, department of cardiology, lifeline superspeciality hospital & heart centre, jhansi, uttar pradesh, india.', 'member, board of directors, the international board of heart rhythm examiners (ibhre); director, department of cardiac pacing and electrophysiology, fortis escorts heart institute, delhi, india.', 'chairman, department of nephrology and renal transplant medicine, max super speciality hospital, delhi, india.', 'professor and head, department of cardiology, sanjay gandhi post graduate institute of medical sciences, lucknow, uttar pradesh, india.', 'senior director, department of cardiac electrophysiology and pacing, medanta-the medicity, gurugram, haryana, india.', 'director, department of cardiology, fortis escorts heart institute, national heart institute of all india heart foundation, delhi, india.', 'consultant cardiologist and head of department, department of cardiology in pd hinduja hospital & medical research centre, mumbai, maharashtra, india.', 'director and head, department of noninvasive cardiology and heart command centre, fortis escorts heart institute; delhi, india.', 'senior director, department of nephrology and renal transplant, max super specialty hospital; delhi, india.', 'adjunct professor cardiology (nbe), chairman, department of clinical and preventive cardiology, medanta heart institute, medanta - the medicity, gurugram, haryana, india.', 'director and consultant diabetologist, lifecare diabetes centre, delhi, india.', 'chairman, department of cardiology, sir ganga ram hospital, delhi, india.']","The rapidly increasing burden of hypertension is responsible for premature deaths from cardiovascular disease (CVD), renal disease, and stroke, with a tremendous public health and financial burden. Hypertension detection, treatment, and control vary worldwide; it is still low, particularly in low- and middle-income countries (LMICs). High blood pressure (BP) and CVD risk have a strong, linear, and independent association. They contribute to alarming numbers of all-cause and CVD deaths. A major culprit for increased hypertension is sympathetic activity, and further complications of hypertension are heart failure, ischemic heart disease (IHD), stroke, and renal failure. Now, antihypertensive interventions have emerged as a global public health priority to reduce BP-related morbidity and mortality. Calcium channel blockers (CCB) are highly effective vasodilators. and the most common drugs used for managing hypertension and CVD. Cilnidipine, with both L- and N-type calcium channel blocking activity, is a promising 4th generation CCB. It causes vasodilation via L-type calcium channel blockade and inhibits the sympathetic nervous system (SNS) via N-type calcium channel blockade. Cilnidipine, which acts as a dual L/N-type CCB, is linked to a reduced occurrence of pedal edema compared to amlodipine, which solely blocks L-type calcium channels. The antihypertensive properties of cilnidipine are very substantial, with low BP variability and long-acting properties. It is beneficial for hypertensive patients to deal with morning hypertension and for patients with abnormal nocturnal BP due to exaggerated sympathetic nerve activation. Besides its BP-lowering effect, it also exhibits organ protection via sympathetic nerve inhibition and renin-angiotensin-aldosterone system inhibition; it controls heart rate and proteinuria. Reno-protective, neuroprotective, and cardioprotective effects of cilnidipine have been well-documented and demonstrated.",2024,Jan 2024,,38736080,,10.59556/japi.71.0400,The Journal of the Association of Physicians of India,"The Promise of Cilnidipine in Hypertension with Comorbidities: National Consensus Statement: National Consensus Group Comprises Cardiologists, Nephrologists, and Diabetologists from India in a National Meet at New Delhi held on 22<sup>nd</sup> May 2022.",88,95,72,1,Humans; Hypertension; Calcium Channel Blockers; Dihydropyridines; India; Antihypertensive Agents; Consensus; Comorbidity,Hypertension; Calcium Channel Blockers; Dihydropyridines,Humans; Hypertension/drug therapy; Calcium Channel Blockers/therapeutic use; Dihydropyridines/therapeutic use; India/epidemiology; Antihypertensive Agents/therapeutic use; Consensus; Comorbidity,,"Journal Article, Consensus Development Conference"
"Cheng RK, Kittleson MM, Beavers CJ, Birnie DH, Blankstein R, Bravo PE, Gilotra NA, Judson MA, Patton KK, Rose-Bovino L, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing",,,,[''],"Cardiac sarcoidosis is an infiltrative cardiomyopathy that results from granulomatous inflammation of the myocardium and may present with high-grade conduction disease, ventricular arrhythmias, and right or left ventricular dysfunction. Over the past several decades, the prevalence of cardiac sarcoidosis has increased. Definitive histological confirmation is often not possible, so clinicians frequently face uncertainty about the accuracy of diagnosis. Hence, the likelihood of cardiac sarcoidosis should be thought of as a continuum (definite, highly probable, probable, possible, low probability, unlikely) rather than in a binary fashion. Treatment should be initiated in individuals with clinical manifestations and active inflammation in a tiered approach, with corticosteroids as first-line treatment. The lack of randomized clinical trials in cardiac sarcoidosis has led to treatment decisions based on cohort studies and consensus opinions, with substantial variation observed across centers. This scientific statement is intended to guide clinical practice and to facilitate management conformity by providing a framework for the diagnosis and management of cardiac sarcoidosis.",2024,May 2024,05/21/2024,38634276,,10.1161/CIR.0000000000001240,Circulation,Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.,e1197,e1216,149,21,Humans; Sarcoidosis; Cardiomyopathies; American Heart Association; United States; Adrenal Cortex Hormones; Disease Management,Sarcoidosis; Cardiomyopathies; American Heart Association,"Humans; Sarcoidosis/therapy, diagnosis; Cardiomyopathies/therapy, diagnosis; American Heart Association; United States/epidemiology; Adrenal Cortex Hormones/therapeutic use; Disease Management","AHA Scientific Statements; cardiomyopathies; inflammation; sarcoidosis; ventricular dysfunction, left","Journal Article, Review"
"Breathett K, Lewsey S, Brownell NK, Enright K, Evangelista LS, Ibrahim NE, Iturrizaga J, Matlock DD, Ogunniyi MO, Sterling MR, Van Spall HGC, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; and Council on Quality of Care and Outcomes Research",,,,[''],"Guideline-directed medical therapies and guideline-directed nonpharmacological therapies improve quality of life and survival in patients with heart failure (HF), but eligible patients, particularly women and individuals from underrepresented racial and ethnic groups, are often not treated with these therapies. Implementation science uses evidence-based theories and frameworks to identify strategies that facilitate uptake of evidence to improve health. In this scientific statement, we provide an overview of implementation trials in HF, assess their use of conceptual frameworks and health equity principles, and provide pragmatic guidance for equity in HF. Overall, behavioral nudges, multidisciplinary care, and digital health strategies increased uptake of therapies in HF effectively but did not include equity goals. Few HF studies focused on achieving equity in HF by engaging stakeholders, quantifying barriers and facilitators to HF therapies, developing strategies for equity informed by theory or frameworks, evaluating implementation measures for equity, and titrating strategies for equity. Among these HF equity studies, feasibility was established in using various educational strategies to promote organizational change and equitable care. A couple include ongoing randomized controlled pragmatic trials for HF equity. There is great need for additional HF implementation trials designed to promote delivery of equitable guideline-directed therapy.",2024,May 2024,05/07/2024,38567497,,10.1161/CIR.0000000000001231,Circulation,Implementation Science to Achieve Equity in Heart Failure Care: A Scientific Statement From the American Heart Association.,e1143,e1163,149,19,Heart Failure; Humans; American Heart Association; United States; Implementation Science; Health Equity; Healthcare Disparities,Heart Failure; American Heart Association; Implementation Science; Health Equity,"Heart Failure/therapy, diagnosis; Humans; American Heart Association; United States; Implementation Science; Health Equity; Healthcare Disparities",AHA Scientific Statements; health disparities; health equity; heart failure; heart transplant; implementation science; pragmatic clinical trials as topic; race factors; womenâ€™s health,"Journal Article, Review"
"Armoundas AA, Narayan SM, Arnett DK, Spector-Bagdady K, Bennett DA, Celi LA, Friedman PA, Gollob MH, Hall JL, Kwitek AE, Lett E, Menon BK, Sheehan KA, Al-Zaiti SS, American Heart Association Institute for Precision Cardiovascular Medicine; Council on Cardiovascular and Stroke Nursing; Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular Radiology and Intervention; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; and Stroke Council",,,,[''],"A major focus of academia, industry, and global governmental agencies is to develop and apply artificial intelligence and other advanced analytical tools to transform health care delivery. The American Heart Association supports the creation of tools and services that would further the science and practice of precision medicine by enabling more precise approaches to cardiovascular and stroke research, prevention, and care of individuals and populations. Nevertheless, several challenges exist, and few artificial intelligence tools have been shown to improve cardiovascular and stroke care sufficiently to be widely adopted. This scientific statement outlines the current state of the art on the use of artificial intelligence algorithms and data science in the diagnosis, classification, and treatment of cardiovascular disease. It also sets out to advance this mission, focusing on how digital tools and, in particular, artificial intelligence may provide clinical and mechanistic insights, address bias in clinical studies, and facilitate education and implementation science to improve cardiovascular and stroke outcomes. Last, a key objective of this scientific statement is to further the field by identifying best practices, gaps, and challenges for interested stakeholders.",2024,Apr 2024,04/02/2024,38415358,PMC11042786,10.1161/CIR.0000000000001201,Circulation,Use of Artificial Intelligence in Improving Outcomes in Heart Disease: A Scientific Statement From the American Heart Association.,e1028,e1050,149,14,United States; Humans; Artificial Intelligence; American Heart Association; Heart Diseases; Cardiovascular Diseases; Stroke,Heart Diseases; Cardiovascular Diseases; Stroke,"United States; Humans; Artificial Intelligence; American Heart Association; Heart Diseases; Cardiovascular Diseases/therapy, prevention & control; Stroke/diagnosis, prevention & control","AHA Scientific Statements; artificial intelligence; electrocardiography; electronic health records; ethics; genetics; heart diseases; monitoring, physiologic","Journal Article, Review"
"Blumer V, Kanwar MK, Barnett CF, Cowger JA, Damluji AA, Farr M, Goodlin SJ, Katz JN, McIlvennan CK, Sinha SS, Wang TY, American Heart Association Cardiovascular Disease in Older Populations Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Council on Cardiovascular Surgery and Anesthesia",,,,[''],"Cardiogenic shock continues to portend poor outcomes, conferring short-term mortality rates of 30% to 50% despite recent scientific advances. Age is a nonmodifiable risk factor for mortality in patients with cardiogenic shock and is often considered in the decision-making process for eligibility for various therapies. Older adults have been largely excluded from analyses of therapeutic options in patients with cardiogenic shock. As a result, despite the association of advanced age with worse outcomes, focused strategies in the assessment and management of cardiogenic shock in this high-risk and growing population are lacking. Individual programs oftentimes develop upper age limits for various interventional strategies for their patients, including heart transplantation and durable left ventricular assist devices. However, age as a lone parameter should not be used to guide individual patient management decisions in cardiogenic shock. In the assessment of risk in older adults with cardiogenic shock, a comprehensive, interdisciplinary approach is central to developing best practices. In this American Heart Association scientific statement, we aim to summarize our contemporary understanding of the epidemiology, risk assessment, and in-hospital approach to management of cardiogenic shock, with a unique focus on older adults.",2024,Apr 2024,04/02/2024,38406869,PMC11067718,10.1161/CIR.0000000000001214,Circulation,Cardiogenic Shock in Older Adults: A Focus on Age-Associated Risks and Approach to Management: A Scientific Statement From the American Heart Association.,e1051,e1065,149,14,"Humans; Aged; Shock, Cardiogenic; American Heart Association; Treatment Outcome; Heart-Assist Devices; Heart Transplantation",Heart-Assist Devices; Heart Transplantation,"Humans; Aged; Shock, Cardiogenic/diagnosis, epidemiology, therapy; American Heart Association; Treatment Outcome; Heart-Assist Devices; Heart Transplantation","AHA Scientific Statements; aging; decision making; frailty; heart transplantation; heart-assist devices; risk assessment; shock, cardiogenic","Journal Article, Review"
"Batra AS, Silka MJ, Borquez A, Cuneo B, Dechert B, Jaeggi E, Kannankeril PJ, Tabulov C, Tisdale JE, Wolfe D, American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology, Council on Basic Cardiovascular Sciences, Council on Cardiovascular and Stroke Nursing, Council on Genomic and Precision Medicine, and Council on Lifelong Congenital Heart Disease and Heart Health in the Young",,,,[''],"Disorders of the cardiac rhythm may occur in both the fetus and neonate. Because of the immature myocardium, the hemodynamic consequences of either bradyarrhythmias or tachyarrhythmias may be far more significant than in mature physiological states. Treatment options are limited in the fetus and neonate because of limited vascular access, patient size, and the significant risk/benefit ratio of any intervention. In addition, exposure of the fetus or neonate to either persistent arrhythmias or antiarrhythmic medications may have yet-to-be-determined long-term developmental consequences. This scientific statement discusses the mechanism of arrhythmias, pharmacological treatment options, and distinct aspects of pharmacokinetics for the fetus and neonate. From the available current data, subjects of apparent consistency/consensus are presented, as well as future directions for research in terms of aspects of care for which evidence has not been established.",2024,Mar 2024,03/05/2024,38314551,,10.1161/CIR.0000000000001206,Circulation,Pharmacological Management of Cardiac Arrhythmias in the Fetal and Neonatal Periods: A Scientific Statement From the American Heart Association: Endorsed by the Pediatric & Congenital Electrophysiology Society (PACES).,e937,e952,149,10,"Infant, Newborn; United States; Child; Humans; American Heart Association; Arrhythmias, Cardiac; Tachycardia; Fetus; Electrophysiology","American Heart Association; Arrhythmias, Cardiac","Infant, Newborn; United States; Child; Humans; American Heart Association; Arrhythmias, Cardiac/diagnosis, drug therapy; Tachycardia; Fetus; Electrophysiology","AHA Scientific Statements; arrhythmias, cardiac; fetus; heart block; infant, newborn; pharmacology; tachycardia","Journal Article, Review"
"Baddour LM, Esquer Garrigos Z, Rizwan Sohail M, Havers-Borgersen E, Krahn AD, Chu VH, Radke CS, Avari-Silva J, El-Chami MF, Miro JM, DeSimone DC, American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young (Young Hearts); and Council on Clinical Cardiology",,,,[''],"The American Heart Association sponsored the first iteration of a scientific statement that addressed all aspects of cardiovascular implantable electronic device infection in 2010. Major advances in the prevention, diagnosis, and management of these infections have occurred since then, necessitating a scientific statement update. An 11-member writing group was identified and included recognized experts in cardiology and infectious diseases, with a career focus on cardiovascular infections. The group initially met in October 2022 to develop a scientific statement that was drafted with front-line clinicians in mind and focused on providing updated clinical information to enhance outcomes of patients with cardiovascular implantable electronic device infection. The current scientific statement highlights recent advances in prevention, diagnosis, and management, and how they may be incorporated in the complex care of patients with cardiovascular implantable electronic device infection.",2024,Jan 2024,01/09/2024,38047353,,10.1161/CIR.0000000000001187,Circulation,"Update on Cardiovascular Implantable Electronic Device Infections and Their Prevention, Diagnosis, and Management: A Scientific Statement From the American Heart Association: Endorsed by the International Society for Cardiovascular Infectious Diseases.",e201,e216,149,2,"United States; Humans; American Heart Association; Communicable Diseases; Endocarditis, Bacterial; Cardiovascular Infections; Cardiology; Defibrillators, Implantable","Communicable Diseases; Endocarditis, Bacterial; Cardiovascular Infections; Cardiology; Defibrillators, Implantable","United States; Humans; American Heart Association; Communicable Diseases/diagnosis, epidemiology, therapy; Endocarditis, Bacterial/drug therapy; Cardiovascular Infections; Cardiology; Defibrillators, Implantable/adverse effects","AHA Scientific Statements; defibrillators, implantable; diagnosis; echocardiography, transesophageal; endocarditis; infection","Journal Article, Review"
